首页> 外文期刊>Beneficial Microbe >Effect of fermented milk containing Lactobacillus casei strain Shirota on constipation-related symptoms and haemorrhoids in women during puerperium
【24h】

Effect of fermented milk containing Lactobacillus casei strain Shirota on constipation-related symptoms and haemorrhoids in women during puerperium

机译:含干酪乳杆菌Shirota的发酵乳对产后妇女便秘相关症状和痔疮的影响

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Constipation and haemorrhoids are common complaints after childbirth. The objective of this pilot study was to evaluate impact of fermented milk containing Lactobacillus casei strain Shirota (LcS) on stool consistency and frequency, constipation-related symptoms and quality of life, and incidence of haemorrhoids in women during puerperium. Forty women who had natural childbirth were randomised to group consuming either one bottle/day of fermented milk containing at least 6.5x10(9) cfu of LcS, or placebo, for 6 weeks after childbirth. Subjects filled in a diary on their bowel habits including number of bowel movement, stool consistency and incidence of haemorrhoids, and answered questionnaires on constipation-related symptoms (PAC-SYM) and quality of life (PAC-QOL) during the study period. The probiotic group showed the better scores on overall PAC-SYM (P=0.013), PAC-SYM subscales of abdominal symptoms (P=0.043) and rectal symptoms (P=0.031), and PAC-QOL satisfaction subscale (P=0.037) in comparison with the placebo group. In the probiotic group, two to four subjects experienced haemorrhoids during the first 3 weeks of treatment. The number decreased in week 4 and no one had haemorrhoids on most days in week 5-6. In the placebo group, on average four subjects had haemorrhoids from the beginning, and no obvious change was observed until week 6. No statistically significant effect was observed on stool consistency and frequency. The study products did not cause any adverse event in the subjects. Results of this study indicate that continuous consumption of fermented milk containing LcS might alleviate constipation-related symptoms, provide satisfactory bowel habit and result in earlier recovery from haemorrhoids in women during puerperium. Nonetheless, there are several limitations in interpretation of the results attributed to the study design, including lack of baseline data. Further study is required in order to confirm the efficacy.
机译:便秘和痔疮是分娩后的常见不适。这项初步研究的目的是评估含干酪乳杆菌Shirota(LcS)的发酵乳对产妇产后粪便稠度和频率,便秘相关症状和生活质量以及痔疮发生率的影响。 40名自然分娩的妇女被随机分组​​,在分娩后6周内每天服用一瓶/天至少含6.5x10(9)cfu LcS的发酵乳或安慰剂。受试者填入日记,记录其排便习惯,包括排便次数,粪便稠度和痔疮发生率,并回答研究期间便秘相关症状(PAC-SYM)和生活质量(PAC-QOL)的问卷。益生菌组在总体PAC-SYM(P = 0.013),腹部症状的PAC-SYM分量表(P = 0.043)和直肠症状(P = 0.031)和PAC-QOL满意度分量表(P = 0.037)上得分更高与安慰剂组相比。在益生菌组中,有2至4名受试者在治疗的前3周内经历了痔疮。在第4周,该数量下降,在第5-6周的大部分时间里,没有人患有痔疮。在安慰剂组中,平均有四名受试者从一开始就患有痔疮,并且直到第6周都没有观察到明显的变化。在大便稠度和频率上没有观察到统计学显着的影响。研究产品未在受试者中引起任何不良事件。这项研究的结果表明,连续食用含LcS的发酵乳可能会缓解便秘相关症状,提供令人满意的排便习惯,并能使妇女在产褥期从痔疮中早日康复。尽管如此,在解释归因于研究设计的结果时仍存在一些限制,包括缺乏基线数据。需要进一步研究以确认疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号